FY2026 Earnings Estimate for IDXX Issued By Leerink Partnrs

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Investment analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for IDEXX Laboratories in a report released on Monday, April 21st. Leerink Partnrs analyst D. Clark now anticipates that the company will earn $13.64 per share for the year, down from their prior estimate of $13.80. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.93 per share.

Other analysts also recently issued research reports about the stock. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 12th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Morgan Stanley cut their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler upped their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $523.75.

IDEXX Laboratories Price Performance

IDXX stock opened at $426.63 on Wednesday. The stock’s 50 day moving average is $420.23 and its two-hundred day moving average is $429.89. IDEXX Laboratories has a 52-week low of $356.14 and a 52-week high of $548.88. The company has a market capitalization of $34.57 billion, a PE ratio of 39.98, a P/E/G ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Tidal Investments LLC raised its position in shares of IDEXX Laboratories by 7.6% during the 3rd quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock worth $3,188,000 after buying an additional 444 shares in the last quarter. Franklin Resources Inc. increased its position in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after purchasing an additional 34,305 shares during the period. American Trust acquired a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $757,000. Oddo BHF Asset Management Sas bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $1,128,000. Finally, GAMMA Investing LLC lifted its holdings in shares of IDEXX Laboratories by 3.3% in the fourth quarter. GAMMA Investing LLC now owns 1,533 shares of the company’s stock valued at $634,000 after buying an additional 49 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.